Hundreds more people surviving heart failure in UK, independent study finds

11 August 2017

Improvements in patient care in the UK mean hundreds more people are surviving heart failure, a new independent study has found.

A report published today has found that the mortality rate for people admitted to hospital with heart failure has dropped from 9.6% to 8.9%. The reduction in the mortality rate means that in the region of 500 lives have been saved in the past year compared to 2014/15.

An assessment of patients admitted to hospital with heart failure at National Health Service (NHS) Trusts also shows that more people are being provided with crucial medicines for heart disease as well as greater access to treatment by heart specialists.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK